Fig. 5

Fig. 5

Response to targeted therapy in P1. a Patient P1 at 5 months of age. b Patient P1 at 6 months of age (after a bleeding episode). c Patient P1 at 28 months of age, showing a significant and progressive enlargement of the right cheek due to the AVM. d MRI (transversal T2 STIR) of the Patient P1 before the start of trametinib treatment; red dashed line indicates the extent of the AVM. e MRI (transversal T2 TSE Dixon) of the Patient P1 after 5 months of treatment with trametinib; red dashed line indicates the now smaller extent of the AVM. f Patient P1 at 38 months of age, reduced volume of the right cheek and fading of the capillary malformation can be noted